Wendy Corbett
About Wendy Corbett
Wendy Corbett is the Vice President, Cell Therapy Therapeutic Area Head at Bristol Myers Squibb, with over 15 years of experience in regulatory affairs within the pharmaceutical industry.
Company
Wendy Corbett is currently serving as the Vice President, Cell Therapy Therapeutic Area Head at Bristol Myers Squibb. She operates out of the company's Summit, New Jersey location. Bristol Myers Squibb is a global pharmaceutical company known for discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases.
Title
As the Vice President, Cell Therapy Therapeutic Area Head at Bristol Myers Squibb, Wendy Corbett leads critical initiatives within the cell therapy domain. Her role involves overseeing therapeutic area strategies, contributing to clinical development, and ensuring regulatory compliance of cell therapy products.
Education and Expertise
Wendy Corbett holds a Ph.D. in Organic/Medicinal Chemistry from Purdue University and an MBA in Pharmaceutical-Chemical Studies from Fairleigh Dickinson University. She has also engaged in studies at Scripps Research. With over 15 years of experience in regulatory affairs within the pharmaceutical industry, Wendy brings a wealth of knowledge in both global and U.S. regulatory environments.
Background
Wendy Corbett transitioned from a scientific research background to a leadership role in regulatory affairs over the course of her career. She previously worked at Celgene in various roles, including Executive Director of Global Regulatory Affairs Hematology-Oncology. She also held positions at Hoffmann-La Roche as a Regulatory Affairs professional. Her extensive experience includes contributing to the regulatory strategy for multiple hematology-oncology products and leading regulatory efforts for new drug applications and biologics license applications.
Achievements
Wendy Corbett has a track record of contributing to the successful approval of several new drug applications (NDAs) and biologics license applications (BLAs). During her tenure at Celgene, she played a key role in the global regulatory strategy for hematology-oncology products. Her work in regulatory affairs has been instrumental in bringing innovative therapies to the market, demonstrating her expertise and dedication in this specialized field.